ASBMR 2012: Anabolics and post-marketing studies
25 October 2012
Critical Pharma links with academia on osteoporosis nasal spray
17 February 2012
Drug's effect on reduction of new hip fractures is greatest influence on Rxing decisions, says DR report
5 March 2010
Zosano patch equivalent to Lilly's Forteo
8 April 2009
Zosano complete end-of-Ph II ZP-PTH meeting with FDA
15 December 2008
UK's NICE issues final guidance on osteoporosis prevention
3 November 2008
Zosano sees good results for PTH Patch
22 September 2008
Lilly pays $35M for TP's osteoperosis patch
23 June 2008
CHMP recommends Lilly's Forsteo
3 March 2008
Lilly's 2nd-qtr 20% sales hike beats estimates
30 July 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Lilly's income down 81%, but shares up 1.5%
12 February 2007
Lilly reiterates 2006/07 guidance, disappoints
18 December 2006
Eli Lilly PAP approved, patients hit by Part D loophole
9 October 2006
Lilly swings to 2nd-qtr 2006 EPS of $0.76
31 July 2006
Osteoporosis market moves in France
10 July 2006
Eli Lilly profit up 6% in 1st-qtr 2006
1 May 2006
Lilly swings to 4th-qtr 2005 profit
6 February 2006
Lilly and Alkermes enter oral PTH accord
16 January 2006
Complex result in Forteo vs Fosamax trial
15 August 2005
Lilly swings to loss in 2nd qtr on settlement
1 August 2005
Strong 2003 sales for Lilly but profits flat
9 February 2004
New Chemical Entities in 2003
19 January 2004
Eli Lilly's Forsteo launched in EU
10 November 2003
Launches hit Lilly's profits, sales strong
27 October 2003
Indian firms win US approvals, other news
6 October 2003
...while Lilly says Forteo has significant benefits over Fosamax
29 September 2003
EU clears Lilly's Forsteo for osteoporosis
30 June 2003
Underlying growth beats forecasts at Lilly
28 April 2003
NPS drug for osteoporosis on track in Ph II/III
10 March 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Lilly unit bids to grow Japanese market share
13 January 2003
Lilly's teriparatide backed for EU approval
6 January 2003
Lilly and FDA talking about plant problems
7 January 2002
Lilly and FDA talking about plant problems
19 December 2001
Xigris still on track for US approval?
23 October 2001
CORRECTION: Eli Lilly's PTH therapy
20 August 2001
Promising data for Lilly/ET oral osteoporosis drug
6 August 2001
Lilly's Forteo lowers fracture risk
11 May 2001
Lilly's Zovant fast-tracked in USA
30 March 2001
Showing 1-53 of 53 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
